Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Marker Therapeutics Inc (MRKR)

Marker Therapeutics Inc (MRKR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Marker Therapeutics Inc 9350 Kirby Drive Suite 300 Houston TX 77054 USA

www.markertherapeutics.com P: 713-400-6400

Description:

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T Cell Therapy, TPIV200 and TPIV100/110 which are in clinical stage. Marker Therapeutics Inc., formerly known as TapImmune Inc., is based in FL, United States.

Key Statistics

Overview:

Market Capitalization, $K 44,997
Enterprise Value, $K 29,887
Shares Outstanding, K 8,919
Annual Sales, $ 3,310 K
Annual Net Income, $ -8,240 K
Last Quarter Sales, $ 1,240 K
Last Quarter Net Income, $ -2,390 K
EBIT, $ -12,080 K
EBITDA, $ -8,400 K
60-Month Beta 1.53
% of Insider Shareholders 17.35%
% of Institutional Shareholders 22.39%
Float, K 7,372
% Float 82.65%
Short Volume Ratio 0.33

Growth:

1-Year Return -27.23%
3-Year Return -77.17%
5-Year Return -90.61%
5-Year Revenue Growth 1,476.19%
5-Year Earnings Growth 90.48%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.27 on 05/15/24
Next Earnings Date 08/12/24
Earnings Per Share ttm -1.08
EPS Growth vs. Prev Year 52.63%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 01/27/23

MRKR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % -248.94%
Debt/Equity 0.00
Price/Sales 14.84
Price/Cash Flow N/A
Price/Book 4.17
Book Value/Share 1.32
Interest Coverage -0.88
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar